VINC Biotech Penny Stock Followup Swing Trades
Updated
VINC was a penny stock and is now in the near penny category as this biotech stock has had
a great run in the past 10 days. On the 30 minute chart, 225 shares are bought at low prices
and 125 shares are sold for profit with 100 shares still running as the momentum slows.
Overall, the trades where profitable averaging 12% daily in an average trade of 4.5 days.
Time and effort in the trade were minimal as the price action was monitored by alerts
and notifications as to price to moving average and moving average to moving average crosses
as well as dips and peaks of RSI under 40 or over 70 to notify for potential buys or sells
in this zig-zag strategy which intended to optimize profit and minimize time and effort
in trading.
a great run in the past 10 days. On the 30 minute chart, 225 shares are bought at low prices
and 125 shares are sold for profit with 100 shares still running as the momentum slows.
Overall, the trades where profitable averaging 12% daily in an average trade of 4.5 days.
Time and effort in the trade were minimal as the price action was monitored by alerts
and notifications as to price to moving average and moving average to moving average crosses
as well as dips and peaks of RSI under 40 or over 70 to notify for potential buys or sells
in this zig-zag strategy which intended to optimize profit and minimize time and effort
in trading.
Trade active
VINC continues to rise another partial of 25 shares closed in great profit.Note
Trade active
Swing trade ongoing 25 shares bough and 25 different shares sold. Price ata flat top. Looking for resistance to break.
Trade closed: target reached
See the link will close this premarket and look to borrow shares to sell shortNote
Note
Price has retreated enough and put in an inside candle. IT could reverse the downtrend tomorrow and finish out the week in good form
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.